Lexeo Therapeutics’ $100 Million Initial Public Offering

Paul Hastings LLP advised the underwriters in connection with Lexeo Therapeutics’ IPO. Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to transforming…

This content is for Standard 1 Year members only.
Login Join Now
Sonia Carcano

Author: Sonia Carcano

This content is for Standard 1 Year members only.
Login Join Now